Spes Immunotherapeutics
PrivateCompany Overview
Spes Immunotherapeutics operates in Healthcare & Life Sciences and is based in Sant Cugat del Vallès. It was founded in 2024.
Spes Immunotherapeutics is a biotechnology company that develops personalized therapeutic vaccines to prevent leukemia relapse in children.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Spes Immunotherapeutics Comparables
Compare Spes Immunotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kindling Bio | 75% | |
| BioNTech SE | 70% | |
| Evaxion A/S | 68% |
For institutional investors. Book with your work email.
Spes Immunotherapeutics Funding Rounds
Historical fundraising activity
Spes Immunotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Spes Immunotherapeutics's valuation, stock price, and market status.
Is Spes Immunotherapeutics a public or private company?
Spes Immunotherapeutics is a private company.
What is the current stock price of Spes Immunotherapeutics?
Spes Immunotherapeutics is a private company, so its shares have no public market price. Caplight tracks Spes Immunotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Spes Immunotherapeutics worth (valuation)?
Valuation information for Spes Immunotherapeutics is not publicly available.
Can I buy Spes Immunotherapeutics stock?
Spes Immunotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Spes Immunotherapeutics's last funding round?
Funding round information for Spes Immunotherapeutics is not publicly available.
Who are the main investors in Spes Immunotherapeutics?
Investor information for Spes Immunotherapeutics is not publicly disclosed.
Will Spes Immunotherapeutics IPO soon?
No public IPO plans have been announced for Spes Immunotherapeutics.
How can I track Spes Immunotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Spes Immunotherapeutics's shares on secondary markets.